 | • レポートコード：MRC2203A764 • 出版社/出版日：Mordor Intelligence / 2022年1月 • レポート形態：英文、PDF、112ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療 |
| Single User | ￥703,000 (USD4,750) | ▷ お問い合わせ |
| Site Licence | ￥962,000 (USD6,500) | ▷ お問い合わせ |
| Corporate License | ￥1,295,000 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の本調査資料では、世界の前部ブドウ膜炎治療市場について調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、治療別（コルチコステロイド、シクロプレジック剤、抗TNF剤、免疫抑制剤）分析、流通チャネル別（病院薬局、小売薬局、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米）分析、競争状況、市場機会・将来の傾向などの項目を掲載しています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界の前部ブドウ膜炎治療市場規模：治療別（コルチコステロイド、シクロプレジック剤、抗TNF剤、免疫抑制剤） ・世界の前部ブドウ膜炎治療市場規模：流通チャネル別（病院薬局、小売薬局、その他） ・世界の前部ブドウ膜炎治療市場規模：地域別（北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米） ・競争状況（AbbVie Inc.、Aldeyra Therapeutics, Inc.、Alimera Sciences Inc.、...） ・市場機会・将来の傾向 |
The anterior uveitis treatment market will show rapid growth due to the increasing cases of the uveitis and the development of novel drugs and treatments and it is expected to grow with a CAGR of 5.8% over the forecasted period.
There has been an increasing prevalence of uveitis as it is responsible for an estimated 30,000 new cases of legal blindness annually in the United States and accounts for about 10–15% of all cases of total blindness in the country. Uveitis is a sight-threatening inflammatory disease affecting the uveal layer of the eye. Redness of eyes, blurring of the vision, the small size of the pupil, and sensitivity to light can be possible symptoms of anterior uveitis, which, if not treated, can result in permanent blindness. Thus, there are new developments in the applications of products and treatment modalities that are ongoing.
New treatment options for uveitis such as corticosteroids and anti-inflammatory drugs are already gaining traction in the market. In addition, other factors such as the growing geriatric population, rising incidence of the disease, and new product developments are also expected to be some of the driving factors in the growth of the market.
Key Market Trends
Corticosteroids Segment is Expected to Dominate the Treatment Type Segment During the Forecast Period
Corticosteroids are found dominating the anterior uveitis treatment market as they are first-line therapies for anterior uveitis and are used in the form of eye drops. They are the most preferred option over biologics however researchers are currently exploring biological therapies for the treatment of anterior uveitis.
Corticosteroids are also used in sustained release treatment, i.e., in ocular implants. It has thus shown significant results to cure the condition and researchers are also exploring biological therapies to treat anterior uveitis. In addition, corticosteroids and anti-inflammatory drugs are found gaining traction in the market.
North America is Anticipated to Dominate the Anterior Uveitis Treatment Market
North America is found dominating the market owing to the rising prevalence of the uveitis disease in the United States. There is also an increasing number of key players in the region that is leading to the high growth of this regional segment. The other factors resulting in the growth of the market is the growing geriatric population, and increasing investments in research and development by drug manufacturing companies for innovating new treatments such as corticosteroids.
In addition, the market in the Asia Pacific is also expanding fast for the same reasons the markets in North America and Europe are expanding.
Competitive Landscape
There has been a presence of a considerable number of companies that are increasingly adopting strategic initiatives such as new product development, mergers & acquisitions, and regional expansion. Various companies are focusing on organic growth strategies such as product launches, product approvals, and others such as patents and events.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Cases of the Uveitis
4.2.2 Development of Novel Drugs and Treatments
4.3 Market Restraints
4.3.1 High Cost Associated with the Medications
4.3.2 Side Effect Associated with Corticosteroid Treatment
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Treatment Type
5.1.1 Corticosteroids
5.1.2 Cycloplegic Agents
5.1.3 Anti-TNF Agents
5.1.4 Immunosuppressants
5.2 By Distribution Channel
5.2.1 Hospitals Pharmacies
5.2.2 Retail Pharmacies
5.2.3 Others
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 AbbVie Inc.
6.1.2 Aldeyra Therapeutics, Inc.
6.1.3 Alimera Sciences Inc.,
6.1.4 Clearside Biomedical, Inc.
6.1.5 EyePoint Pharmaceuticals, Inc.
6.1.6 Novartis AG
6.1.7 Regeneron Pharmaceuticals
6.1.8 Bausch & Lomb Incorporated
6.1.9 Sirion Therapeutics, Inc.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS